399-30-4

Basic information

• Product Name: (2-FLUOROBENZYL)METHYLAMINE
• Synonyms: (2-FLUOROBENZYL)METHYLAMINE;2-FLUORO-N-METHYLBENZYLAMINE;1-(2-FLUOROPHENYL)-N-METHYLMETHANAMINE;(2-Fluorobenzyl)methylamine95%;(2-FLUOROBENZYL)METHYLAMINE 95%;(2-fluorobenZzyl)methylamine;(2-Fluorobenzyl)Methyla E 95%;(2-FLUOROBENZYL)METH
• CAS NO: 399-30-4
• Molecular Formula: C₈H₁₀FN
• Molecular Weight: 139.17
• Product Categories: Amines;C8;Nitrogen Compounds
• Mol File: 399-30-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 139-140 °C
• Boiling Point: 73 °C12 mm Hg(lit.)
• Flash Point: 155 °F
• Appearance: Colorless to tan/Liquid
• Density: 1.047 g/mL at 25 °C(lit.)
• Vapor Pressure: 1.4mmHg at 25°C
• Refractive Index: n20/D 1.5010(lit.)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.05±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Air Sensitive
• CAS DataBase Reference: (2-FLUOROBENZYL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-FLUOROBENZYL)METHYLAMINE(399-30-4)
• EPA Substance Registry System: (2-FLUOROBENZYL)METHYLAMINE(399-30-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/38
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 399-30-4(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 399-30-4 differently. You can refer to the following data:
1. It is used as a pharmaceutical intermediate.
2. Reactant for:Preparation of biologically and pharmacologically active molecules

InChI:InChI=1/C8H10FN/c1-10-6-7-4-2-3-5-8(7)9/h2-5,10H,6H2,1H3

Upstream product

• 446-48-0 o-fluorobenzyl bromide 
• 74-89-5 methylamine 
• 89-99-6 2-fluorobenzylamine 
• 1159505-61-9 C₈H₇F₄NO₂S 
• 36457-58-6 N-benzyl-1,1,1-trifluoromethanesulfonamide 
• 100-46-9 benzylamine 
• 1159505-77-7 C₉H₉F₄NO₂S 
• 345-35-7 2-fluorobenzyl chloride 
• 153903-21-0 N-(tert-butyloxycarbonyl)-2-fluorobenzylamine 
• 593-51-1 methylamine hydrochloride 
• 446-52-6 2-Fluorobenzaldehyde 

Downstream Products

• 957113-03-0 C₃₄H₄₃F₂N₃O₆ 
• 1174903-49-1 3-[[(2-fluorobenzyl)-methyl-amino]methyl]-5-(pyridin-4-yl)-1,3,4-oxadiazol-2(3H)-one 
• 952492-80-7 3-(3,3-dimethyl-1-oxoisochroman-4-yl)-3H-imidazole-4-carboxylic acid (2-fluorobenzyl)methylamide 
• 1431950-45-6 C₁₉H₂₃FN₂O₂S 
• 1431950-18-3 C₁₅H₁₅BrFNO₂S 

Relevant articles and documents

NECROSIS INHIBITORS

The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigations

3H-1,3,4-Oxadiazol-2-one derivatives were synthesized and tested for their in vitro antimycobacterial activity. Oxadiazolone derivatives showed an interesting antimycobacterial activity against the reference strain of Mycobacterium tuberculosis H37Rv. Molecular modeling investigations were performed and showed that the active compounds possess all necessary features to target the protein active site of the mycobacterial cytochrome P450-dependent sterol 14α-demethylase in the sterol biosynthesis pathway as the calculated free energy of binding were in agreement with the corresponding MIC values.